Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.

Citrome L, Volavka J, Czobor P, Brook S, Loebel A, Mandel FS.

J Clin Psychiatry. 2006 Apr;67(4):638-42.

PMID:
16669729
2.
3.
4.

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW; EUFEST Study Group.

J Clin Psychiatry. 2011 Jul;72(7):955-61. doi: 10.4088/JCP.10m06529.

PMID:
21824456
5.

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN.

J Clin Psychopharmacol. 1998 Aug;18(4):296-304.

PMID:
9690695
6.

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.

Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O'Gorman C, Harrigan RH.

Clin Ther. 2010 Mar;32(3):472-91. doi: 10.1016/j.clinthera.2010.03.003.

PMID:
20399985
7.

The utility of intramuscular ziprasidone in the management of acute psychotic agitation.

Mendelowitz AJ.

Ann Clin Psychiatry. 2004 Jul-Sep;16(3):145-54.

PMID:
15517847
8.

Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.

Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, El Tallawy H, Danaci AE, Lowe W, Karayal ON.

Int Clin Psychopharmacol. 2009 Sep;24(5):229-38. doi: 10.1097/YIC.0b013e32832c2624.

PMID:
19531959
9.

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.

Hirsch SR, Kissling W, Bäuml J, Power A, O'Connor R.

J Clin Psychiatry. 2002 Jun;63(6):516-23.

PMID:
12088164
10.

A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia.

Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J.

Clin Ther. 2003 Feb;25(2):530-41.

PMID:
12749512
11.

Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.

Volavka J, Czobor P, Citrome L, McQuade RD, Carson WH, Kostic D, Hardy S, Marcus R.

J Clin Psychiatry. 2005 Nov;66(11):1362-6.

PMID:
16420071
12.

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.

Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP.

J Clin Psychiatry. 2001 Jan;62(1):12-8. Erratum in: J Clin Psychiatry 2001 Mar;62(3):209.

PMID:
11235922
13.

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.

Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.

CNS Spectr. 2009 Sep;14(9):478-86.

PMID:
19890230
14.

Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.

Kudla D, Lambert M, Domin S, Kasper S, Naber D.

Eur Psychiatry. 2007 Apr;22(3):195-202. Epub 2006 Nov 29.

PMID:
17140769
15.

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.

Keck PE Jr, Reeves KR, Harrigan EP; Ziprasidone Study Group.

J Clin Psychopharmacol. 2001 Feb;21(1):27-35.

PMID:
11199944
16.

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.

Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR.

Psychopharmacology (Berl). 1998 Nov;140(2):173-84.

PMID:
9860108
17.
18.

Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.

Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano R, O'Gorman C, Harrigan RH.

Pharmacotherapy. 2010 Feb;30(2):127-35. doi: 10.1592/phco.30.2.127.

PMID:
20099987
19.
20.

Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study.

Loebel AD, Khanna S, Rajadhyaksha S, Siu CO, Giller E, Potkin SG.

J Clin Psychiatry. 2007 Sep;68(9):1333-8.

PMID:
17915970
Items per page

Supplemental Content

Write to the Help Desk